The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer
Received 10 January 2021
Accepted for publication 10 March 2021
Published 31 March 2021 Volume 2021:13 Pages 2937—2945
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Bilikere Dwarakanath
Faris Abushamma,1– 3 Zain Khayyat,1 Aya Soroghle,1 Sa’ed H Zyoud,4,5 Ahmad Jaradat,1,2 Maha Akkawi,1,6 Hanood Aburass,1,6 Iyad KK Qaddumi,7 Razan Odeh,8 Husam Salameh,8 Salah Albuheissi3
1Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine; 2Department of Urology, An-Najah National University Hospital, Nablus, 44839, Palestine; 3Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK; 4Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, an-Najah National University, Nablus, 44839, Palestine; 5Clinical Research Center, an-Najah National University Hospital, Nablus, 44839, Palestine; 6Department of Pathology, An-Najah National University Hospital, Nablus, 44839, Palestine; 7Department of Urology, Rafedia General Hospital, Nablus, 44839, Palestine; 8Department of Oncology, An-Najah National University Hospital, Nablus, 44839, Palestine
Correspondence: Faris Abushamma
Department of Medicine, College of Medicine and Health Sciences, an-Najah National University, Nablus, 44839, Palestine
Email [email protected]
Purpose: Non-muscle invasive bladder cancer (NMIBC) is a potentially curable or controllable disease if strict adherence to a surveillance protocol is followed. Management and surveillance of NMIBC begins at the time of diagnosis up to a few years thereafter. There is scanty data in the literature evaluating the impact of non-compliance with the surveillance protocols on progression, recurrence, and mortality rate.
Patients and Methods: An observational, retrospective cohort study recruited data between 2012 and 2017 at two tertiary hospitals. Data were collected consecutively. NMIBC patients who had at least 3 years of follow-up data were included. Patients were divided into different groups based on their compliance with the cystoscopy follow-up protocol as recommended by the European guidelines. We compared the cystoscopy compliant group with the non-compliant group in view of recurrence, progression, and mortality. In addition, missing variable items during surveillance were calculated using a new scoring model to predict adverse outcomes.
Results: Eighty-eight NMIBC patients met our criteria. Recurrence rate (RR), progression rate (PR), metastasis rate (MsR), and mortality rate (MR) are significantly higher in non-compliant group, RR: (92.6%) (P< 0.001), PR: (54.1%) (P< 0.001), MsR: (37.7%) (P< 0.001), MR: (23.5%) (P= 0.002) respectively. In the subgroup analysis, intermediate and high-risk groups have a PR rate of zero in the compliant group, while it is 100% (P< 0.001) and 56.4% (P=0.001) in the non-compliant group, respectively. Use of a Kaplan Meier (KM) graph shows that compliant patients had a better survival in comparison to non-compliant patients. Scoring there or more is statistically and clinically significantly associated with higher recurrence, progression, and mortality. RR: (94%) (P=0.016), PR: 49% (P< 0.001) and MR (26%) (P=0.012).
Conclusion: Non-compliance to a standardized surveillance protocol in NMIBC is associated statistically and clinically with adverse outcomes in comparison to a compliant group. This mandates strict adherence to surveillance guidelines particularly in patients with high-risk disease.
Keywords: NMIBC, COVID-19, urological malignancies, haematuria
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]